1780-26-3

Basic information

• Product Name: 4,6-Dichloro-2-methylpyrimidine
• Synonyms: BUTTPARK 52\14-70;2-MDCP;2-METHYL-4,6-DICHLOROPYRIMIDINE;4,6-DICHLORO-2-METHYLPYRIMIDINE;4,6-Dichloro-2-methylpyrimidiine;Pyrimidine, 4,6-dichloro-2-methyl-;4,6-Dichloro-2-methylpyrimidine ,99%;4,6-Dichloro-2-Methylpyrimidine/2,4-dichloro-6-methylpyrimidine
• CAS NO: 1780-26-3
• Molecular Formula: C₅H₄Cl₂N₂
• Molecular Weight: 163
• EINECS: 1806241-263-5
• Product Categories: APIs & Intermediate;Pyrimidine;Halides;Pyrazines, Pyrimidines & Pyridazines;Pyrimidines;Pyrazines, Pyrimidines & Pyridazines;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;PyrimidinesHeterocyclic Building Blocks;Heterocycle-Pyrimidine series;alkyl chloride
• Mol File: 1780-26-3.mol

Chemical Properties

• Melting Point: 41.5-45.5 °C(lit.)
• Boiling Point: 210.8 °C at 760 mmHg
• Flash Point: 208 °F
• Appearance: White to off-white/Crystalline Powder or Crystals
• Density: 1.404 g/cm³
• Vapor Pressure: 0.273mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: -3.84±0.30(Predicted)
• CAS DataBase Reference: 4,6-Dichloro-2-methylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloro-2-methylpyrimidine(1780-26-3)
• EPA Substance Registry System: 4,6-Dichloro-2-methylpyrimidine(1780-26-3)

Safety Data

• Hazard Codes: C,N,Xn
• Statements: 34-51/53-43-22
• Safety Statements: 26-36/37/39-45-61-36/37
• RIDADR: UN 3261 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 1780-26-3(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white solid

InChI:InChI=1/C5H4Cl2N2/c1-3-8-4(6)2-5(7)9-3/h2H,1H3

Synthetic route

2-methyl-4,6-dihydroxypyrimidine (1194-22-5) → 2,4-dichloro-2-methylpyrimidine (1780-26-3)

Conditions	Yield
With trichlorophosphate Heating;	97%
With thionyl chloride In acetonitrile at 80℃; for 3h; Temperature; Concentration; Reagent/catalyst; Industrial scale;	94%
With trichlorophosphate at 95℃; for 18h;	90%

2-methyl-1H-pyrimidine-4,6-dione (40497-30-1) → 2,4-dichloro-2-methylpyrimidine (1780-26-3)

Conditions	Yield
With trichlorophosphate
With N,N-dimethyl-aniline; trichlorophosphate

4,6-Dichloro-2-methyl-1,2-dihydro-pyrimidine → 2,4-dichloro-2-methylpyrimidine (1780-26-3)

Conditions	Yield
With 2,3-dicyano-5,6-dichloro-p-benzoquinone In tetrahydrofuran; diethyl ether for 0.0833333h; Ambient temperature; Yield given;

2,4-dichloro-2-methylpyrimidine (1780-26-3)

Conditions	Yield
With ammonia In methanol at 50℃; for 5h; Solvent; Temperature; Concentration; Industrial scale;	92%
With ammonium hydroxide In ethanol at 140℃; for 1h; Microwave irradiation;	90%
With ammonia In water; isopropyl alcohol regioselective reaction;	83%

Upstream product

• 40497-30-1 2-methyl-1H-pyrimidine-4,6-dione 
• 1194-22-5 2-methyl-4,6-dihydroxypyrimidine 

Downstream Products

• 13566-48-8 2-methyl-4,6-dimethoxypyrimidine 
• 856976-05-1 (6-chloro-2-methyl-pyrimidin-4-yl)-(4-chloro-phenyl)-amine 
• 856976-40-4 6-chloro-2-methyl-N-(4-nitrophenyl)pyrimidin-4-amine 
• 103260-98-6 2,N⁴,N⁴,N⁶,N⁶-pentamethyl-pyrimidine-4,6-diyldiamine 
• 3772-76-7 sulfametomidine 
• 5053-43-0 2-methylpyrimidine 
• 197165-78-9 2-methylpyrimidine-4,6-diamine 
• 17551-52-9 6-chloro-2-methyl-3,4-dihydropyrimidin-4-one 
• 94052-15-0 4-chloro-2-methyl-6-piperidinopyrimidine 
• 76132-88-2 2-methyl-4,6-diphenethylpyrimidine 
• 128381-49-7 acetophenone O-(2-methyl-4-chloropyrimidin-6-yl)oxime 
• 128381-50-0 acetophenone O-(2-methylpyrimidin-4,6-diyl)bisoxime 
• 184241-36-9 4-chloro-2-methyl-6-(2',4',6'-trichloroanilino)pyrimidine 
• 89466-39-7 4-chloro-6-methoxy-2-methylpyrimidine 

Relevant articles and documents

An efficient solid-phase synthesis of 2-alkyl-4,6-diaminopyrimidines and 2,4,6-triaminopyrimidines

An efficient and simple approach for the solid-phase synthesis of 2,4,6-triaminopyrimidines and 2-alkyl-4,6-diaminopyrimidines is described. Primary amines were immobilized on 2-(4-formyl-3-methoxyphenoxy)ethyl polystyrene resin via reductive amination. A

Preparation method of 2-methyl-4-amino-6-chloropyrimidine

The invention discloses a preparation method of 2-methyl-4-amino-6-chloropyrimidine. 4, 6-dihydroxy-2-methylpyrimidine, phosphorus oxychloride, an ammoniation reagent and the like are used as raw materials and subjecting to a two-step reaction to obtain t

IBD-mediated oxidative cyclization of pyrimidinylhydrazones and concurrent Dimroth rearrangement: Synthesis of [1,2,4]triazolo[1,5-c]pyrimidine derivatives

Oxidative cyclization of 6-chloro-4-pyrimidinylhydrazones 4 with iodobenzene diacetate (IBD) in dichloromethane gives rise to [1,2,4]triazolo[4,3-c]pyrimidine derivatives 5a-o. These incipient products undergo feasible Dimroth rearrangement to furnish the isolated [1,2,4]triazolo[1,5-c]pyrimidines 6a-o in moderate to high yields.

A convenient synthesis of 5-arylamino-4H-pyran-4-ones using palladium-catalyzed amination

A concise approach to 5-arylamino-4H-pyran-4-ones is described via palladium-catalyzed amination reaction. The methodology involved in this Letter is based on protection/deprotection protocols and on manipulation of the 5-hydroxy group of readily available kojic acid. It would provide a new entry to a range of 5-arylamino-4H-pyran-4-ones via Buchwald-Hartwig-type amination reaction on 4H-pyran-4-one unit.

1,3,5-Trisubstituted aryls as highly selective PPARδ agonists

A series of highly potent and selective PPARδ agonists is described using the known non-selective ligand GW2433 as a structural template. Compound 1 is bioavailable, potent (10 nM), and shows no cross-activity with other PPAR subtypes up to 10 μM, making it a useful tool in studying the biological effects of selective PPARδ activation.

IL-12 MODULATORY COMPOUNDS

The invention relates to cyclic hydrazone compounds, compositions including the cyclic hydrazone compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and proc

Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists

Compounds of the formula (I): and pharmaceutically acceptable salts or prodrugs thereof, wherein X, Y, Z and R1 are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds o

PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF

The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson’s disease, epilepsy, and addiction.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPARδ .

AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C-Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C-Ar2, with the proviso that when Y is N or CH then Z is C-Ar2, and with the further proviso that when Y is C-Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CONR3R4, NR3SO2R6, SO2NR3R4, -(CH2)mcarboxy, esterified -(CH2)mcarboxy or -(CH2)mNR3R4; R2 represents hydrogen, halogen, hydroxy, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy, haloC1-6alkoxy, unsubstituted phenyl or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; R3 and R4 are each independently hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl or fluoroC1-6alkyl; or R3 and R4 and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C1-4alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, S(O), S(O)2, or NR5; R5 represents hydrogen, C1-4alkyl, hydroxyC1-4alkyl or C1-4alkoxyC1-4alkyl; R6 represents hydrogen, C1-6alkyl, fluoroC1-6alkyl, C3-7cycloalkyl, unsubstituted phenyl, or phenyl substituted with one or two groups selected from halogen, C1-6alkyl, haloC1-6alkyl, C3-7cycloalkyl, C1-6alkoxy or haloC1-6alkoxy; m is either zero or an integer from 1 to 4; n is either zero or an integer from 1 to 3; or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof; a pharmaceutical composition comprising it; its use in methods of treatment; use of it for the manufacture of a medicament for treating VR-1 related conditions such as those in which pain and/or inflammation predominate; and methods of treatment using it.